| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1067/MAI.2003.129 |
| P698 | PubMed publication ID | 12642818 |
| P50 | author | Giorgio Walter Canonica | Q56380976 |
| Giovanni Passalacqua | Q61949008 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 437-48; quiz 449 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
| P1476 | title | Noninjection routes for immunotherapy | |
| P478 | volume | 111 |
| Q52942005 | A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. |
| Q36150445 | Advances in allergen-specific immunotherapy |
| Q38245926 | Allergen immunotherapy, routes of administration and cytokine networks: an update |
| Q35875669 | Allergic rhinitis in children : diagnosis and management strategies |
| Q54420300 | Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. |
| Q34725718 | BSACI guidelines for the management of allergic and non-allergic rhinitis |
| Q39037216 | Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma |
| Q35927387 | CD4-blockade can induce protection from peanut-induced anaphylaxis |
| Q81055255 | Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis |
| Q47149942 | Chinese Guideline on allergen immunotherapy for allergic rhinitis |
| Q46858436 | Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma |
| Q59737295 | Consenso sobre tratamiento del asma en pediatría |
| Q40744033 | Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI). |
| Q33827470 | Construction of a Der p2-transgenic plant for the alleviation of airway inflammation |
| Q36589520 | Construction of a recombinant allergen-producing probiotic bacterial strain: Introduction of a new line for a live oral vaccine against Chenopodium album pollen allergy |
| Q53760201 | Critical appraisal of the clinical utility of sublingual immunotherapy in allergy. |
| Q40119246 | Current and future applications of the anti-IgE antibody omalizumab |
| Q34041905 | Development of a sublingual allergy vaccine for grass pollinosis |
| Q37550576 | Development of an allergen extract for sublingual immunotherapy--evaluation of Staloral |
| Q79429550 | Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study |
| Q80126897 | Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice |
| Q81196215 | Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production |
| Q43515187 | Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial |
| Q35849524 | Efficacy and safety of sublingual immunotherapy |
| Q51104473 | Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. |
| Q37091822 | Efficacy of long-term sublingual-oral immunotherapy in allergic rhinitis. |
| Q34561153 | Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials |
| Q35864547 | Efficacy of sublingual immunotherapy versus subcutaneous injection immunotherapy in allergic patients. |
| Q37046636 | Emerging treatment of atopic dermatitis |
| Q47375550 | Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen. |
| Q42600886 | Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy |
| Q82055864 | Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy |
| Q36515402 | Future developments in sublingual immunotherapy |
| Q57216501 | Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens |
| Q83625718 | High-dose sublingual immunotherapy in children at 8-year follow-up |
| Q34484071 | Immune mechanisms of allergen-specific sublingual immunotherapy |
| Q81203088 | Immunotherapy |
| Q39260807 | Immunotherapy for allergic rhinitis. |
| Q37793242 | Immunotherapy in asthma |
| Q81047272 | Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report |
| Q27022140 | Induction of tolerance via the sublingual route: mechanisms and applications |
| Q38202695 | Investigational drugs for the treatment of allergic rhinitis |
| Q36826600 | Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction |
| Q24187849 | Local nasal immunotherapy for allergic rhinitis |
| Q24242771 | Local nasal immunotherapy for allergic rhinitis |
| Q36383819 | Molecular approaches for new vaccines against allergy |
| Q80178543 | Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis |
| Q26825418 | Nanoparticulate adjuvants and delivery systems for allergen immunotherapy |
| Q30394326 | Needle-free influenza vaccination. |
| Q36561244 | New insights in sublingual immunotherapy |
| Q35605442 | New targets for allergic rhinitis--a disease of civilization |
| Q54242472 | Once daily sublingual immunotherapy without updosing--A new treatment schedule. |
| Q79222907 | Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study |
| Q37873483 | One century of allergen-specific immunotherapy for respiratory allergy |
| Q43560444 | Oral immunotherapy with transgenic rice seed containing destructed Japanese cedar pollen allergens, Cry j 1 and Cry j 2, against Japanese cedar pollinosis |
| Q38068965 | Oralair(®): a causal treatment for grass pollen-induced allergic rhinoconjunctivitis. |
| Q42601969 | Patient's compliance with allergen immunotherapy |
| Q46015098 | Perception and practice of sublingual immunotherapy among practicing allergists. |
| Q38632661 | Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma |
| Q47766233 | Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects |
| Q36561253 | Pollen immunotherapy: selection,prevention, and future directions |
| Q47795423 | Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years |
| Q34580968 | Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy |
| Q30903098 | Ragweed-induced allergic rhinoconjunctivitis: current and emerging treatment options |
| Q45088211 | Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more |
| Q30371972 | Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement |
| Q49175643 | Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial |
| Q38907668 | Safety evaluation of standardized allergen extract of Japanese cedar pollen for sublingual immunotherapy |
| Q52935226 | Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. |
| Q34353492 | Specific immunotherapy by the sublingual route for respiratory allergy |
| Q37950136 | Specific immunotherapy in children: the evidence |
| Q46892026 | Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis |
| Q33577679 | Strategies of mucosal immunotherapy for allergic diseases |
| Q26747200 | Sublingual Immunotherapy: A Useful Tool for the Allergist in Private Practice |
| Q44961338 | Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial |
| Q42056866 | Sublingual immunotherapy in allergic asthma: Current evidence and needs to meet |
| Q37488131 | Sublingual immunotherapy in children: an updated review |
| Q34613104 | Sublingual immunotherapy in children: facts and needs |
| Q38096032 | Sublingual immunotherapy in preschool children: an update |
| Q36583727 | Sublingual immunotherapy of allergic diseases |
| Q46961926 | Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production |
| Q36515397 | Sublingual immunotherapy: efficacy--methodology and outcome of clinical trials |
| Q81055243 | Sublingual swallow immunotherapy in the new world |
| Q37735267 | T-cell responses induced by allergen-specific immunotherapy |
| Q24595355 | The anti-vaccination movement and resistance to allergen-immunotherapy: a guide for clinical allergists |
| Q41904166 | The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children |
| Q37299117 | The effect of caffeic acid phenethyl ester on the functions of human monocyte-derived dendritic cells |
| Q46104089 | The effect of local nasal immunotherapy in allergic rhinitis: using strips of the allergen dermatophagoides pteronyssinus |
| Q38278145 | The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook |
| Q36130311 | The safety of sublingual-swallow immunotherapy: an analysis of published studies |
| Q38002411 | Therapeutic effects and biomarkers in sublingual immunotherapy: a review |
| Q46714664 | Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. |
| Q36404344 | Update on sublingual immunotherapy |
| Q40087434 | Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract |
| Q53514860 | [Immunological mechanisms of allergen-specific immunotherapy]. |
| Q80032598 | [SENP-SEICAP (Spanish Society of Pediatric Pneunomology. Spanish Society of Pediatric Clinical Immunology and Allergology) consensus on asthma, pneumonology, and pediatric allergy (Draft)] |
| Q52648209 | [Specific immunotherapy. Hyposensitization with allergens]. |
Search more.